The IQ MPS is a collaboration of the pharmaceutical and biotechnologies companies created as an Affiliate within the International Consortium for Innovation and Quality in Pharmaceutical Development (also known as the IQ Consortium). The IQ Consortium is a leading science-focused, not-for-profit organization with a mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators and the broader R&D community (https://iqconsortium.org). The IQ MPS Affiliate was established to provide a venue for appropriate cross-pharma collaboration and data sharing to facilitate the industry implementation and qualification of MPS models.
The Steering Committee provides strategic oversight of the initiative's portfolio and is the primary decision-making body for the IQ MPS Affiliate. The Steering Committee has representation from all member companies and acts on the recommendations of working groups and member companies to establish objectives, policies, and plans of action on a consensus basis.
The Executive Committee provides leadership and guidance in the management of the business and affairs of the consortium between meetings of the Steering Committee, implements strategic plans recommended by the Steering Committee, and provides general counsel and tactical advice in support of IQ MPS’s Working Groups.
Alnylam Pharmaceuticals, Inc.
Astellas Pharma US, Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Janssen Pharmaceuticals, Inc.
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Novartis Pharmaceuticals Corporation
Seattle Genetics, Inc.
Vertex Pharmaceuticals Incorporated